Advances in chemotherapy for chronic lymphocytic leukemia

Seminars in Hematology

Volumn 41, Issue 3, 2004, Pages 224-233

  Wendtner, C M ^a   Eichhorst, B F ^b   Hallek, M J ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BRYOSTATIN 1; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEPSIPEPTIDE; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; FLUDARABINE; FR 901228; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; PENTOSTATIN; PREDNISONE; PROTEIN KINASE C INHIBITOR; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW;

EID: 3242681705     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.05.004     Document Type: Article

References (79)

1. Raphael B., Andersen J.W., Silber R., Oken M., Moore D., Bennett J., et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia Long-term follow-up of an Eastern Cooperative Oncology Group randomized trial. J Clin Oncol. 9:1991;770-776
2. Saven A., Lemon R.H., Kosty M., Beutler E., Piro L.D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 13:1995;570-574
3. Tallman M.S., Hakimian D., Zanzig C., Hogan D.K., Rademaker A., Rose E., et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 13:1995;983-988
4. Dillman R.O., Mick R., McIntyre O.R. Pentostatin in chronic lymphocytic leukemia A phase II trial of Cancer and Leukemia Group B. J Clin Oncol. 7:1989;433-438
5. Keating M.J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., et al. Fludarabine A new agent with major activity against chronic lymphocytic leukemia. Blood. 74:1989;19-25
6. Israels L.G., Galton D.A.G., Till M., Wiltshaw E. Clinical evaluation of CB 1348 in malignant lymphoma and related diseases. Ann NY Acad Sci. 68:1958;915-925
7. Begleiter A., Mowat M., Israels L.G., Johnston J.B. Chlorambucil in chronic lymphocytic leukemia Mechanism of action. Leuk Lymphoma. 23:1996;187-201
8. Montserrat E., Fontanilles M., Estape J. Treatment of chronic lymphocytic leukemia A preliminary report of Spanish (PETHEMA) trials. Leuk Lymphoma. 5:(suppl):1991;89-91
9. Sawitsky A., Rai K.R., Glidewell O., Silver R.T. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 50:1977;1049-1059
10. Jaksic B., Brugiatelli M., Krc I., Losonczi H., Hoowiecki J., Planinc-Peraica A., et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer. 79:1997;2107-2114
11. Jaksic B., Brugiatelli M. High dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL IGCI CLL-01 trial. Nouv Rev Fr Hematol. 30:1988;437-442
12. Han T., Ezdinli E.Z., Shimaoka K., Desai D.V. Chlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer. 31:1973;502-508
13. Montserrat E., Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev. 7:1993;164-175
14. Hansen M.M., Andersen E., Birgeus H., Christensen B.E., Christensen T.G., Gisler C. CHOP versus prednisone + chlorambucil in chronic lymphocytic leukemia Preliminary results of a randomized multicenter study. Nouv Rev Fr Hematol. 30:1998;433-436
15. CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia A meta-analysis of the randomized trials. J Natl Cancer Inst. 91:1999;861-868
16. Keating M.J., O'Brien S., Lerner S., Koller C., Beran M., Robertson L.E., et al. Long term follow-up of patient with CLL receiving fludarabine regimens as initial therapy. Blood. 92:1998;65-71
17. Johnson S., Smith A.G., Löffler H., Osby E., Juliusson G., Emmerich B., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 347:1996;1432-1438
18. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 343:2000;1750-1757
19. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98:2001;2319-2325
20. Keating M.J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 81:1993;2878-2884
21. Eichhorst B.F., Busch R., Stauch M., Kneba M., Ritgen M., Söling U., et al. Fludarabine induces higher response rates in first line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil Interim analysis of a phase III study of the German CLL Study Group. Blood. 102:2003;109. (abstr)
22. Boogaerts M.A., Van Hoof A., Catovsky D., Kovacs M., Montillo M., Zinzani P.L., et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 19:2001;4252-4258
23. Robak T., Blasinska-Morawiec M., Blonski J.Z., Krykowski E., Komarnicki M., Trepinska E., et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur J Cancer. 33:1997;2347-2351
24. Robak T., Blonski J.Z., Kasznicki M., Blasinska-Morawiec M., Krykowski E., Dmoszynska A., et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia Report of a prospective, randomized, multicenter trial. Blood. 96:2000;2723-2729
25. Dillman R.O., Mick R., McIntyre O.R. Pentostatin in chronic lymphocytic leukemia A phase II trial of Cancer and Leukemia Group B. J Clin Oncol. 7:1989;433-438
26. Ho A.D., Thaler J., Stryckmans P., Coiffier B., Luciani M., Sonneveld P., et al. Pentostatin in refractory chronic lymphocytic leukemia A phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst. 82:1990;1416-1420
27. Plunkett W., Gandhi V., Huang P., Robertson L.E., Yang L.Y., Gregoire V., et al. Fludarabine Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 20:1993;2-12
28. O'Brien S. Clinical challenges in chronic lymphocytic leukemia. Semin Hematol. 35:1998;22-26
29. O'Brien S.M., Kantarjian H.M., Cortes J., Beran M., Koller C.A., Giles F.J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 19:2001;1414-1420
30. Eichhorst B.F., Hopfinger G., Pasold R., Hensel M., Söling U., Siehl S., et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL) Results of a phase III study (CLL4 protocol) of the German CLL Study Group (GCLLSG). Blood. 102:2003;72. (abstr)
31. Hallek M., Schmitt B., Wilhelm M., Busch R., Krober A., Fostitsch H.P., et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL) Results of a phase II study of the German CLL Study Group. Br J Haematol. 114:2001;342-348
32. Bosch F., Ferrer A., Lopez-Guillermo A., Gine E., Bellosillo B., Villamor N., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol. 119:2002;976-984
33. Schmitt B.F., Burkhard O., Schlag R., Hopfinger G., Stauch M., Bergmann M., et al. Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukaemia (CLL) with or without G-CSF Results of a first interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood. 100:2002;364. (abstr)
34. Robertson L.E., O'Brien S., Kantarjian H., Koller C., Beran M., Andreeff M., et al. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 9:1995;943-945
35. Rummel M.J., Kafer G., Pfreundschuh M., Jager E., Reinhardt U., Mitrou P.S., et al. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia A German multicenter phase II study. Ann Oncol. 10:1999;183-188
36. Rummel M.J., Gamm H., Rost A., Gruenhagen U., Wojatschek C., Jäger E., et al. Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia (CLL) - Results of a randomized phase-III multicenter study. Blood. 102:2002;437. (abstr)
37. O'Brien S., Kantarjian H., Beran M., Smith T., Koller C., Estey E., et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 82:1993;1695-1700
38. Anaissie E.J., Kontoyiannis D.P., O'Brien S., Kantarjian H., Robertson L., Lerner S., et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 129:1998;559-566
39. Morrison V.A., Rai K.R., Peterson B.L., Kolitz J.E., Elias L., Appelbaum F.R., et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 19:2001;3611-3621
40. Gandhi V., Robertson L.E., Keating M.J., Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia Clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 34:1994;30-36
41. Mauro F.R., Foa R., Meloni G., Gentile M., Giammartini E., Giannarelli D., et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica. 87:2002;926-933
42. Van Den Neste E., Bontemps F., Delacauw A., Cardoen S., Louviaux I., Scheiff J.M., et al. Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′- deoxyadenosine. Leukemia. 13:1999;918-925
43. Robak T., Blonski J.Z., Kasznicki M., Gora-Tybor J., Dwilewicz-Trojaczek J., Stella-Holowiecka B., et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J. 3:2002;244-250
44. Montillo M., Tedeschi A., O'Brien S., Di Raimondo F., Lerner S., Ferrajoli A., et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 97:2003;114-120
45. Tefferi A., Li C.Y., Reeder C.B., Geyer S.M., Allmer C., Levitt R., et al. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia. 15:2001;1171-1175
46. Robak T., Blonski J.Z., Kasznicki M., Gora-Tybor I., Dwilewicz-Trojaczek J., Boguradzki P., et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia. 15:2001;1510-1516
47. Robak T., Gora-Tybor J., Lech-Maranda E., Blonski J.Z., Kasznicki M. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol. 66:2001;188-194
48. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol. 128:2002;603-609
49. Aivado M., Schulte K., Henze L., Burger J., Finke J., Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia Results and future perspectives. Semin Oncol. 29:(suppl 13):2002;19-22
50. Bergmann M., Herold M., Wilhelm M., Emmerich B., Boening L., Hallek M. High efficacy and better hematological safety of reduced dose of bendamustin in extendedly pretreated patients with advanced, relapsed or refractory B-CLL Phase I/II study of the German CLL Study Group. Proc Am Soc Clin Oncol. 22:2003;590. (abstr)
51. Kath R., Blumenstengel K., Fricke H.J., Höffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 127:2001;48-54
52. Chow K.U., Boehrer S., Geduldig K., Krapohl A., Hoelzer D., Mitrou P.S., et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 86:2001;485-493
53. Weide R., Heymanns J., Gores A., Koppler H. Bendamustine mitoxantrone and rituximab (BMR) A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma. 43:2002;327-331
54. Konig A., Schwartz G.K., Mohammad R.M., Al-Katib A., Gabrilove J.L. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood. 90:1997;4307-4312
55. Byrd J.C., Shinn C., Waselenko J.K., Fuchs E.J., Lehman T.A., Nguyen P.L., et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 92:1998;3804-3816
56. Byrd J.C., Shinn C., Willis C.R., Flinn I.W., Lehman T., Sausville E., et al. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol. 29:2001;703-708
57. Drexler H.G., Gignac S.M., Jones R.A., Scott C.S., Pettit G.R., Hoffbrand A.V. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood. 74:1989;1747-1757
58. Mohammad R.M., Katato K., Almatchy V.P., Wall N., Liu K.Z., Schultz C.P., et al. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine preclinical studies. Clin Cancer Res. 4:1998;445-453
59. Roberts J.D., Feldman E.J., Smith M.R., Grant S. Phase I trial of bryostatin 1 (NSC 339555) and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Blood. 100:2002;385. (abstr)
60. Byrd J.C., Shinn C., Ravi R., Willis C.R., Waselenko J.K., Flinn I.W., et al. Depsipeptide (FR901228) A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 94:1999;1401-1408
61. Bruner R.J., Marcucci G., Binkley P., Xiao J., Chan K., Parthun M., et al. Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228) in fludarabine refractory chronic lymphocytic leukemia. Blood. 100:2002;385. (abstr)
62. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 102:2003;652-658
63. Frankel S.R. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia A targeted approach to enhance apoptosis. Semin Oncol. 30:2003;300-304
64. Rai K.R., O'Brien S., Cunningham C., Turkina A.G., Ochoa L., Frankel S.R., et al. Genasense (Bcl-2 Antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia Phase I and II results. Blood. 100:2002;384. (abstr)
65. Banerjee D. Genasense (Gena Inc.). Curr Opin Invest Drugs. 2:2001;574-580
66. O'Brien S., Kantarjian H., Beran M., Koller C., Talpaz M., Lerner S., et al. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 11:1997;1631-1635
67. Flinn I.W., Byrd J.C., Morrison C., Jamison J., Diehl L.F., Murphy T., et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 96:2000;71-75
68. Siakantaris M.P., Angelopoulou M.K., Vassilakopoulos T.P., Dimopoulo M.N., Kontopidou F.N., Pangalis G.A. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin Maintenance is necessary to sustain response. Leuk Lymphoma. 40:2000;141-147
69. Osterborg A., Brandberg Y., Molostova V., Iosava G., Abdulkadyrov K., Hedenus M., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol. 20:2002;2486-2494
70. Pangalis G.A., Siakantaris M.P., Angelopoulou M.K., Vassilakopoulos T.P., Dimopoulou M.N., Kyrtsonis M.C., et al. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica. 87:2002;500-506
71. Ludwig H., Rai K., Blade J., Dammacco F., Degos L., Itri L., et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia Epoetin treatment recommendations. Hematol J. 3:2002;121-130
72. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 36:2000;453-471
73. Bernardi D., Milan I., Balzarotti M., Spina M., Santoro A., Tirelli U. Comprehensive geriatric evaluation in elderly patients with lymphoma Feasibility of a patient-tailored treatment plan. J Clin Oncol. 24:2003;754-756
74. Kennedy B., Rawstron A., Carter C., Ryan M., Speed K., Lucas G., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 99:2002;2245-2247
75. Keating M., Manshouri T., O'Brien S., Wierda W., Kantarijan H., Washington L., et al. A high proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukaemia. Blood. 100:2002;205. (abstr)
76. Cazin B., Maloum K., Divine M., Lepretre S., Travade P., Delmer A., et al. Oral fludarabine and cyclophosphamide in previously untreated chronic lymphocytic leukaemia (CLL) Preliminary data on 75 patients. Blood. 100:2002;200. (abstr)
77. Flinn I.W., Jemiai Y., Bennett J.M., Falkson C.I., Flynn P., Pundaleeka S., et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia ECOG 1997. Blood. 98:2001;150. (abstr)
78. O'Brien S., Kantarjian H., Keating M.J. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol. 7:(suppl):1996;27-33
79. Giles F.J., O'Brien S., Santini V., Gandhi V., Plunkett W., Seymour J.F., et al. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia A phase II study. Leuk Lymphoma. 36:1999;57-65. cytic leukemia: A phase II study. Leuk Lymphoma 36:57-65, 1999